Ascletis Selected Oral ASC30 and ASC48 Combination for Obesity Clinical Development

ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...

July 17, 2026 | Friday | News
Sapphiros Secures BARDA-Backed RRPV Agreement to Advance Portable Molecular Diagnostics

Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings  ...

July 16, 2026 | Thursday | News
Mesoblast Completes Target Enrollment in Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  announced that it has achieved ...

July 15, 2026 | Wednesday | News
Zelluna Doses First Patient in Phase 1 Trial of ZI-MA4-1 TCR-NK Cell Therapy

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...

July 15, 2026 | Wednesday | News
What Future UK Regulation of AI in Healthcare Looks Like Now

  While we will need to wait for the National Commission into the Regulation of AI in Healthcare's recommendations later this summer, and then the MH...

July 14, 2026 | Tuesday | Expert Opinion
Warburg Pincus Set to Acquire Pantherx Rare in Deal Valued at Over US$7 Billion

Private equity firm Warburg Pincus is reportedly close to acquiring Pantherx Rare, a leading US specialty pharmacy focused on rare and orphan diseases, in ...

July 13, 2026 | Monday | News
Vivani Medical Signs Agreement with Novo Nordisk to Evaluate NPM-139 Obesity Implant

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company specializing in the development of innovative dr...

July 13, 2026 | Monday | News
BioLineRx and Hemispherian Report Promising Preclinical Data for GLIX1-Olaparib Combination in Ovarian Cancer

Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared t...

July 10, 2026 | Friday | News
Alberta Cancer Foundation Commits $35 Million to Expand Cancer Clinical Trials Across Alberta

The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta. The amount represents one of the largest investment...

July 08, 2026 | Wednesday | News
Aspen Neuroscience Completes Dosing in Phase 1/2a ASPIRO Trial Cohorts for Parkinson's Cell Therapy

Advancement of commercial-ready formulation supports scalability and late-stage development Aspen Neuroscience, Inc., a clinical-stage regenerative medi...

July 02, 2026 | Thursday | News
Bavarian Nordic Receives Health Canada Approval for VIMKUNYA Chikungunya Vaccine

Bavarian Nordic A/S announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikung...

June 30, 2026 | Tuesday | News
AstraZeneca and YMCA of the USA Launch Five-Year Partnership to Expand Cancer Screening and Survivorship Support

Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities AstraZen...

June 26, 2026 | Friday | News
Pfizer Expands IBRANCE Label with FDA Approval in HR+, HER2+ Metastatic Breast Cancer

First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 ...

June 26, 2026 | Friday | News
Abu Dhabi and Biocom California Establish Strategic Gateway Linking Two Leading Life Sciences Ecosystems

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest ...

June 25, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close